Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter.
Stock Region Penny Picks Watchlist Newsletter - Today's Key Updates (2/20/2025)
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. Always conduct your own research or consult a financial advisor before making investment decisions.
$NIVF - NewGen
NewGen has received continued Nasdaq listing approval, ensuring its compliance with the exchange's requirements. The company also announced the appointment of a new Business Development Director, signaling a focus on growth and strategy refinement.
$APTO - Aptose Biosciences
Aptose has received approval from the Clinical Safety Review Committee (CSRC) to escalate dosing in its Phase 1/2 Tuscany Trial for frontline triple drug therapy with Tuspetinib. The first cohort has shown complete responses and favorable safety, marking significant progress in cancer treatment development.
$BTTR - Better Choice Company
Better Choice has reached an agreement in principle to license its Halo Elevate® brand in Asia. This move reflects the company’s efforts to expand its global reach and capitalize on the growing demand for premium pet products.
$NEGG - Newegg
Newegg has launched the new NVIDIA RTX 5070 Ti GPUs alongside ABS Gaming PCs. This release positions the company as a key player in the gaming and tech markets, appealing to performance-driven consumers.
$PRPH - ProPhase Labs
ProPhase Labs has reported excellent progress with Crown Medical Collections. They are targeting over $50 million in net near-term cash recovery from outstanding COVID-19 receivables, which could bolster their financials significantly.
$BRTX - BioRestorative Therapies
BioRestorative has received FDA Fast Track Designation for its BRTX-100 program targeting chronic lumbar disc disease. This designation could accelerate the development and review process for this innovative treatment.
$HEPA - Hepion Pharmaceuticals
A new US patent application (#20250057807) has been published highlighting Hepion’s work on disease treatments involving a pharmaceutically active ingredient in a pseudo-ternary phase system. This technology has shown activity in treating liver disease, hepatitis, and HIV, signaling strong potential for future development.
Disclaimer: All content provided in this newsletter is for informational purposes only and should not be considered as investment recommendations. Stock Region does not guarantee the accuracy or reliability of the information provided.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net